Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series - Wikidata - wikimedia - TriplyDB

Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series

Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series

http://www.wikidata.org/entity/Q34244966

about

The search for novel analgesics: targets and mechanisms Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists Receptor heteromerization and drug discovery.Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes Building a new conceptual framework for receptor heteromers Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics Opioid receptor trafficking and interaction in nociceptors Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function Opioid receptors: toward separation of analgesic from undesirable effects Opioid receptor heteromers in analgesia Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism Structure-guided development of heterodimer-selective GPCR ligands Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base.Cannabinoid-opioid interactions during neuropathic pain and analgesia.Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.Bi- or multifunctional opioid peptide drugs.Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery?Search for the "ideal analgesic" in pain treatment by engineering the mu-opioid receptor.Opioid-receptor-heteromer-specific trafficking and pharmacology.Role of antibodies in developing drugs that target G-protein-coupled receptor dimers.Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.The year in G protein-coupled receptor research.Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects.N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers Design strategies for bivalent ligands targeting GPCRs.Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.Mu and delta opioid receptors on nociceptors attenuate mechanical hyperalgesia in rat.Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain.A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.Discovery of GPCR ligands for probing signal transduction pathways.Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.In vivo opioid receptor heteromerization: where do we stand?

P2860

Q24288817-CDD22BFB-5350-47EC-84D1-54D8807F13EC Q24597777-790A9093-DFC5-48C4-A4FA-9F2F2E592821 Q24630645-DA119D5E-967F-47A0-8B89-D5D53D28A1F5 Q24630886-D62A4211-3778-4333-BB3B-DBA07BCD7926 Q24631212-E19F52B4-0864-4BDF-8B84-F76AF4D647E2 Q24631740-14D3F462-FBE4-466B-AD23-37CBA1BACD3C Q24633877-32D8A5B8-690E-4FCF-94E9-ABF157348B61 Q24644975-70D5CC8F-6D97-4615-8D7B-1F5B7B60B9C3 Q24647687-DA6F255B-DD73-4BE8-94D7-D2C1E386326F Q26822251-E598C61A-3681-4A20-A8BD-35ECE3A7B86D Q26992192-0AFEC421-4584-4BD3-BE3C-B290CE1429EF Q27002925-198B01E8-717C-4862-BAF2-97E8CEC8B521 Q27004306-1B3E16E5-1426-4E9B-879F-BD1AD5531254 Q28488120-350B61EF-44C5-489C-8090-C84BA2BF7DA1 Q28828634-8F0DE03F-C07C-48B2-89B0-A9EE9610060F Q33286209-957D91B7-5474-409C-9BA7-ACCE6ADEC1B0 Q33637224-E2D219D9-D204-4637-9180-1BE833056FF9 Q33693780-8B9C1C16-865B-4D1B-BFF8-DDE8482C7738 Q33767037-E19E6B76-8F91-4BA3-83DB-F96190B85B84 Q33767121-9489CA4A-CE3B-4E09-9F29-5E5DE61367FE Q33807778-78F8014E-23FE-4DB9-8A24-4B5DBD706E0D Q33978499-32182E05-9615-4765-9325-8815BD21AE94 Q34051430-26230B5C-10D0-4E91-B70E-201EAF7CB890 Q34061067-7BCAD45E-5E4F-4ACE-B10B-800AF0E67F2E Q34077604-C40A555A-5C23-45EA-ADC4-3EEA13482756 Q34088801-3D2B0290-1832-47B6-84F3-70A85A6D23B4 Q34145241-F23C0928-0989-4F2A-96FF-561544627106 Q34169318-00F98C3C-1BE3-4842-8AF6-44657A6A997E Q34180510-D1B26C8E-DF4B-43DE-89F3-19BC0E9AFA3D Q34191032-7D066ED4-FE11-4EF7-8E4D-C65D21DF3B1D Q34209429-BE2982CB-C1DB-4B29-B5E3-81948EAC4A6A Q34354902-7D0DFD1D-80A2-4600-9551-792136944487 Q34424009-FB52BEEA-5459-4169-839F-89CE206BB245 Q34497517-3FB19AFA-C64D-4FBD-9334-145E603B7D13 Q34517465-7C5D5349-A30F-488D-B9C0-B9250B8EBA8A Q34524896-39E4C344-7DFE-4AED-8071-C6845AA5F87A Q34550143-C3BC82DD-D9B8-434F-B1F3-60C57B00B23C Q34582707-528A8FF2-6B0B-4025-BB38-02E168B7507F Q34939624-8BBF7B54-C89B-468C-B40E-158210BA0503 Q34939677-3DADC2EF-B1CB-4F0B-93C7-33E809C68DCD

P2860

Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series

http://www.wikidata.org/entity/Q34244966

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@ast

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@en

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@nl

type

label

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@ast

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@en

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@nl

prefLabel

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@ast

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@en

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@nl

P1433

Q34244966-2CBF241B-706F-486A-8C7F-93E1181DAA24

P1476

Q34244966-59B6A5A6-8C7A-49E0-AF55-C3AF79D8F8C6

P2093

Q34244966-1FD6A7CA-7709-429C-9300-5A2E8667CCBB

Q34244966-AC340BA2-7BE1-4563-9916-59BDCCC8B100

Q34244966-D13C16EA-2626-4941-A94B-12AE488BC2CB

Q34244966-FDBDB52C-D24D-4106-B19D-D91A6E70C1A3

Q34244966-FEE94582-97A3-4557-A4A0-50C512E678DA

P2860

Q34244966-02EB2F96-6DC2-4894-A66F-17865859F24B

Q34244966-08B29DFB-328C-4AC9-84C2-1D7699E4DF52

Q34244966-13128754-4C53-4BF6-8D9A-93D6773F7690

Q34244966-2E05A06C-926D-4D68-86F0-398307A3D5A9

Q34244966-306EE325-B65D-4A60-86A6-625B429B396C

Q34244966-3A847CD7-6EF8-4794-9E3D-AF886ED17849

Q34244966-47403003-F042-4EF1-AE2E-D1ABB24C507D

Q34244966-518CF918-BE6B-4032-85E1-A89169A14C59

Q34244966-5725DD7A-DF4C-4F01-9B29-395E9F14663C

Q34244966-5ED79D22-59DE-415C-B0EF-93C4648C6BAE

P304

Q34244966-3C5343CA-CDE2-4964-8C9C-13AE41B540B8

P31

Q34244966-2894FDBC-4023-4F7C-98C7-1B32741BB27F

P356

Q34244966-5BEFC757-CB93-45DD-817C-96BBCE5EE8B4

P407

Q34244966-FBD98003-DF4B-440E-A03A-43A731BDBABC

P433

Q34244966-04F2A304-A153-4735-BEAB-257E97B4C0D4

P478

Q34244966-597C3A1C-785E-42B1-B0B5-96550FD423FA

P50

Q34244966-352D768F-23A8-4AC4-BB3E-73E7EFF1A493

P577

Q34244966-28A5E548-6F4A-49DE-BA41-5AD48CF1CC61

P5875

Q34244966-299B43E7-7443-4E9A-8C0C-6BC7CBD55B43

P698

Q34244966-0EF6679E-785A-4173-BDA8-1E57A26B1AC9

P921

Q34244966-6c579c1f-cf8c-4225-a44e-83dc165c3801

P932

Q34244966-965EF2E6-F561-4D0D-96B6-E9366486691E

P356

PNAS.0506627102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Opioid-induced tolerance and d ...... es in a bivalent ligand series

@en

P2093

Chris L Etienne

http://www.w3.org/2001/XMLSchema#string

David J Daniels

http://www.w3.org/2001/XMLSchema#string

Natalie R Lenard

http://www.w3.org/2001/XMLSchema#string

Philip S Portoghese

http://www.w3.org/2001/XMLSchema#string

Sandra C Roerig

http://www.w3.org/2001/XMLSchema#string

P2860

A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Design of peptidomimetic delta opioid receptor antagonists using the message-address concept

Hybrid bivalent ligands with opiate and enkephalin pharmacophores

In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.

Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids.

Opioid agonist and antagonist bivalent ligands as receptor probes.

Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites.

A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia

Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors.

Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells.

P304

19208-19213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0506627102

http://www.w3.org/2001/XMLSchema#string

P407

P433

52

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7405960

http://www.w3.org/2001/XMLSchema#string

P698

16365317

http://www.w3.org/2001/XMLSchema#string

P921

P932

1323165

http://www.w3.org/2001/XMLSchema#string